Category: Uncategorized

Nov 17 2024

Uncategorized

Bristol Rockets 11% As Investors Question AbbVie’s $8.7 Billion ‘Mistake’ – Investor’s Business Daily

by Clinical Editor

No Comments

Bristol Rockets 11% As Investors Question AbbVie’s $8.7 Billion ‘Mistake’  Investor’s Business Daily

Nov 17 2024

Uncategorized

People Are Opening Up About What It’s Like To Have Schizophrenia, And It’s Incredibly Interesting

by Clinical Editor

No Comments

I recently came across this question on Quora: “What is it like to have schizophrenia?” The thread led me to many other related questions where people with schizophrenia shared their...

Nov 16 2024

Uncategorized

Psychedelic use linked to higher risk of schizophrenia

by Clinical Editor

No Comments

Study links hallucinogen use to higher schizophrenia risk, highlighting the need for caution and informed decisions on psychedelic use.

Nov 16 2024

Uncategorized

Taking drugs like LSD and ecstasy can increase your risk of schizophrenia, according to new study

by Clinical Editor

No Comments

Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like Kristen Bell and Aaron Rodgers publicly sharing their experiences.

Nov 15 2024

Uncategorized

3 Things to Know About Cobenfy, the New Schizophrenia Drug – Yale Medicine

by Clinical Editor

No Comments

3 Things to Know About Cobenfy, the New Schizophrenia Drug  Yale Medicine

Nov 15 2024

Uncategorized

FDA approves Cobenfy for adults with schizophrenia

by Clinical Editor

No Comments

The U.S. Food and Drug Administration has approved Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Nov 14 2024

Uncategorized

Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia

by Clinical Editor

No Comments

Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased risk of schizophrenia after ER treatment for psychedelics use. Hallucinogens include drugs...

Nov 14 2024

Uncategorized

Despite setback, AbbVie’s big bet on neuroscience has yet to play out

by Clinical Editor

No Comments

For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the effort might not get any easier.

Nov 13 2024

Uncategorized

AbbVie’s Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio

by Clinical Editor

No Comments

AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy.

Nov 13 2024

Uncategorized

Glial Cells May Influence Depression and Schizophrenia

by Clinical Editor

No Comments

New research highlights neuroglia (or glia cells) as critical players in mental health, potentially influencing conditions like depression and schizophrenia.